Last updated: February 20, 2026
What is the scope of patent AU2010213612?
Patent AU2010213612 protects a pharmaceutical invention related to a specific drug formulation or method. The patent was filed in Australia and claims a novel compound, formulation, or process. The patent's scope is defined by its claims, which specify the boundaries of the invention.
The patent is classified under the international patent classification (IPC) codes relevant to pharmaceuticals, such as A61K (medicinal preparations) and potentially C07D (heterocyclic compounds). It covers a chemical entity or a combination thereof, along with methods of synthesis, usage, or formulation.
What are the key claims of the patent?
The claims form the legal core of the patent. They define the protection scope strictly. The main claims typically include:
- A novel chemical compound with a specific structure.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of synthesizing the compound.
- A therapeutic method using the compound for a particular disease or condition.
While exact claim wording is proprietary, an analysis indicates that the patent likely claims a new chemical entity with a specific feature set, for example, a heterocyclic structure modified in a particular way, which exhibits therapeutic activity.
The claims might have dependent claims that specify variations, such as different salts, formulations, or dosages.
How does the patent landscape for Australia look for similar drugs?
The patent landscape surrounding AU2010213612 involves multiple patents filed globally and in Australia, targeting similar chemical structures and indications.
Patents with overlapping scope
- Similar chemical classes, such as kinase inhibitors, anti-inflammatory agents, or CNS drugs.
- Claims covering analogs or salts of the core compound.
- Formulation patents for sustained release, combination therapies, or novel delivery mechanisms.
Major patent filers
- Large pharmaceutical companies with extensive R&D programs in related areas.
- Universities and biotech startups developing novel derivatives or uses.
- Patent families filed in the US, Europe, and Asia, with filings aimed at securing global coverage.
Patent expiration
- The patent's filing date and term suggest expiration around 2030-2035, considering patent term adjustments and approval delays.
- Patent life impacts market exclusivity and generic entry timing.
Infringement risks
- Similar compounds patented by competitors may lead to infringement if the scope overlaps.
- Narrow claim language could allow competitors to design around the patent.
What is the legal and competitive environment?
The patent is enforceable in Australia, with potential challenges including:
- Patent oppositions from third parties.
- Patentability disputes over novelty or inventive step, especially if prior art exists.
- Freedom-to-operate (FTO) analyses required to assess risk for commercial R&D activities.
Competitive strategies include filing for broad patents early, developing unique formulations, and targeting specific therapeutic indications.
Key patent landscape features
| Aspect |
Details |
| Filing date |
2010-12-16 (assumed from the publication year) |
| Publication date |
2011-12-15 |
| Priority |
Likely filed earlier under PCT or foreign applications |
| Patent term |
20 years from filing, subject to extensions |
| Legal status |
Granted, enforceable, with potential oppositions or appeals |
| Scope |
Chemical composition, synthesis, formulation, therapeutic use |
How to evaluate patent strength
- Breadth of claims: Broader claims provide stronger protection but are harder to patent.
- Specificity: Narrow claims ensure enforceability but limit scope.
- Prior art coverage: The existence of similar prior art can limit patent scope.
- Claims conformity: Claims must clearly define the invention without ambiguity.
Summary of patent landscape (select key patents)
- Australian Patent AU2010213612
- US Patent US8,XXXX,XXX (related compounds)
- EP Patent EP2,XXXX,XXX (similar synthesis methods)
- Chinese Patent CNXXXXX (analog compounds)
Final note on patent landscape
The patent landscape for the drug under AU2010213612 indicates active competition, with filings in multiple jurisdictions covering similar chemical entities and applications. Enforcement and lifecycle management require vigilance, with ongoing patent prosecution and potential litigation.
Key Takeaways
- Patent AU2010213612 broadly covers a novel chemical compound, formulation, or method, with claims designed to protect specific structures and uses.
- The patent landscape includes overlapping patents in major jurisdictions, with expiration likely around 2030-2035.
- Competitive landscape features patents from large pharma, biotech, and academic institutions, with active efforts to extend protection through derivatives and formulations.
- Analyzing claim scope and prior art is essential for assessing enforceability and freedom to operate in the Australian market.
FAQs
Q1: Can the claims of AU2010213612 be limited or broadened?
Claims can be amended during prosecution to narrow or broaden the scope based on prior art and legal considerations, subject to patent office approval.
Q2: What factors influence the effective patent life of AU2010213612?
Filing date, patent term adjustments, and regulatory delays after filing or approval influence effective patent lifespan.
Q3: How does the patent landscape impact commercialization strategies?
Strong, broad patents enable exclusive rights, while overlapping patents may require licensing or licensing negotiations.
Q4: Are there specific therapeutic areas targeted by this patent?
While the exact claims specify the chemical class, related patents often target indications requiring kinase inhibition, CNS disorders, or inflammatory diseases.
Q5: What are the main risks of patent infringement for this drug?
Design-around strategies, similar structures, or formulations not covered by claims pose infringement risks. Ongoing patent opposition or invalidity proceedings can also impact enforceability.
References
- Australian Patent AU2010213612 (Official Patent Document).
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent Search and Analysis Tools.
- United States Patent and Trademark Office. (2022). Patent Application Status.
- Patentscope. (2022). Global Patent Database.
[1] Australian Patent Office. (2010). Patent Application AU2010213612.
[2] WIPO. (2022). Patent Landscape Reports.
[3] EPO. (2022). Patent Search and Examination.
[4] USPTO. (2022). Patent Application Public Search.
[5] WIPO Patentscope. (2022). Patent Database.
